NCT07010835View on ClinicalTrials.gov

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2028

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
DRUG

YK012

YK012 is a bispecific antibody targeting CD19 and CD3.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Excyte Biopharma Ltd

INDUSTRY